Related Experiment Video
Updated: Jul 16, 2026
14:34
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Chemically targeting the PI3K family
1Howard Hughes Medical Institute, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.
Biochemical Society Transactions
|March 21, 2007
Summary
Phosphoinositide 3-kinase (PI3K) pathway activation drives cancer. Researchers are developing potent and selective PI3K inhibitors, highlighting recent progress and remaining challenges in targeting this crucial cancer pathway.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Phosphoinositide 3-kinase (PI3K) is integral to cellular functions including growth, metabolism, and survival.
- Aberrant PI3K pathway signaling is frequently observed in various human cancers.
- Targeting the PI3K pathway offers a promising therapeutic strategy for cancer treatment.
Purpose of the Study:
- To review recent advancements in the development of PI3K inhibitors.
- To discuss the challenges associated with achieving potent and selective inhibition of PI3K isoforms.
- To provide an overview of the current landscape of PI3K-targeted cancer therapy.
Main Methods:
- Literature review of recent scientific publications.
- Analysis of preclinical and clinical studies on PI3K inhibitors.
- Synthesis of data on inhibitor efficacy, selectivity, and challenges.
Main Results:
- Significant progress has been made in identifying novel PI3K inhibitors with improved selectivity.
- Several PI3K inhibitors have demonstrated promising preclinical and early clinical activity.
- Challenges remain in overcoming resistance mechanisms and achieving isoform-specific targeting.
Conclusions:
- The development of PI3K inhibitors represents a dynamic area of cancer research.
- Targeting the PI3K pathway holds significant therapeutic potential for a range of cancers.
- Continued research is essential to address the remaining challenges and optimize PI3K-targeted therapies.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:42Phosphoinositides and PIPs
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
01:11IP3/DAG Signaling Pathway
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...